Identification of diagnosis and prognosis gene markers in B-ALL with ETV6-RUNX1 fusion by Integrated Bioinformatics Analysis

Gene ◽  
2022 ◽  
pp. 146132
Author(s):  
Hongkai Zhu ◽  
Rong Zhang ◽  
Ruijuan Li ◽  
Zhihua Wang ◽  
Heng Li ◽  
...  
2019 ◽  
Vol Volume 12 ◽  
pp. 4517-4532 ◽  
Author(s):  
Fangfang Dai ◽  
Gantao Chen ◽  
Yanqing Wang ◽  
Li Zhang ◽  
Youmei Long ◽  
...  

2020 ◽  
Author(s):  
Qiliang Peng ◽  
Yi Shen ◽  
Peifeng Zhao ◽  
Ming Cheng ◽  
Yaqun Zhu ◽  
...  

Abstract Background: Recent studies have extensively investigated the roles of miR-106 in colorectal cancer (CRC). However, the associations and molecular mechanism underlying the roles of miR-106 in CRC remain unclear. We aimed to thoroughly investigate the biomarker roles of miR-106 for predicting the risk and survival outcome in CRC.Methods: We first conducted a comprehensive meta-analysis to quantitatively evaluate the roles of miR-106 in the diagnosis and prognosis of CRC. Then, we qualitatively explored the biomarker roles of miR-106 in CRC through an integrative bioinformatics analysis. Results: The results indicated that miR-106 yielded a combined AUC of 0.79 (95% CI: 0.76–0.83), with a pooled sensitivity of 0.50 (95% CI: 0.32–0.68) and a pooled specificity of 0.93 (95% CI: 0.79–0.98) for discriminating CRC cases from normal controls. Moreover, patients with higher expression of miR-106 were significantly associated with shorter disease-free survival (HR: 1.73; 95%CI: 1.23-2.44) and overall survival (HR: 1.39; 95%CI: 1.09-1.77). Finally, gene ontology and pathway analysis demonstrated that miR-106 family was highly involved in the initiation and progression of CRC and indicated the potential molecular mechanism for miR-106 in CRC.Conclusions: Our results indicated that miR-106 showed promising potential as diagnostic and prognostic biomarker for CRC. Nevertheless, the underlying molecular mechanism of miR-106 family involved in CRC requires further investigation.


Medicine ◽  
2021 ◽  
Vol 100 (28) ◽  
pp. e26632
Author(s):  
Dinglong Yang ◽  
Xiaodong Gu ◽  
Chunjiang Li ◽  
Junjun Shi ◽  
Yujing Chen ◽  
...  

2019 ◽  
Author(s):  
Qiliang Peng ◽  
Yi Shen ◽  
Peifeng Zhao ◽  
Ming Cheng ◽  
Yaqun Zhu ◽  
...  

Abstract Background: Recent studies have extensively investigated the roles of miR-106 in colorectal cancer (CRC). However, the associations and molecular mechanism underlying the roles of miR-106 in CRC remain unclear. We aimed to thoroughly investigate the biomarker roles of miR-106 for predicting the risk and survival outcome in CRC.Methods: We first conducted a comprehensive meta-analysis to quantitatively evaluate the roles of miR-106 in the diagnosis and prognosis of CRC. Then, we qualitatively explored the biomarker roles of miR-106 in CRC through an integrative bioinformatics analysis. Results: The results indicated that miR-106 yielded a combined AUC of 0.79 (95% CI: 0.76–0.83), with a pooled sensitivity of 0.50 (95% CI: 0.32–0.68) and a pooled specificity of 0.93 (95% CI: 0.79–0.98) for discriminating CRC cases from normal controls. Moreover, patients with higher expression of miR-106 were significantly associated with shorter disease-free survival (HR: 1.73; 95%CI: 1.23-2.44) and overall survival (HR: 1.39; 95%CI: 1.09-1.77). Finally, gene ontology and pathway analysis demonstrated that miR-106 family was highly involved in the initiation and progression of CRC and indicated the potential molecular mechanism for miR-106 in CRC.Conclusions: Our results indicated that miR-106 showed promising potential as diagnostic and prognostic biomarker for CRC. Nevertheless, the underlying molecular mechanism of miR-106 family involved in CRC requires further investigation.


2020 ◽  
Vol 11 ◽  
Author(s):  
Xingyu Chen ◽  
Yi Jin ◽  
Lian Gong ◽  
Dong He ◽  
YaXing Cheng ◽  
...  

2019 ◽  
Vol 13 (2) ◽  
pp. 265-274 ◽  
Author(s):  
Kai Xue ◽  
Jinfeng Cao ◽  
Yinan Wang ◽  
Xue Zhao ◽  
Dan Yu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document